Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast

Dermatol Ther. 2022 Aug;35(8):e15610. doi: 10.1111/dth.15610. Epub 2022 Jun 7.

Authors

Paolo Romita¹, Caterina Foti¹, Gianluca Calianno¹, Andrea Chiricozzi^{2

3}

Affiliations

¹ Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy.
² Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
³ Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents* / therapeutic use
Arthritis, Psoriatic* / drug therapy
HIV Infections* / complications
HIV Infections* / drug therapy
Humans
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Thalidomide
secukinumab
apremilast